JP2024540994A5 - - Google Patents

Info

Publication number
JP2024540994A5
JP2024540994A5 JP2024524371A JP2024524371A JP2024540994A5 JP 2024540994 A5 JP2024540994 A5 JP 2024540994A5 JP 2024524371 A JP2024524371 A JP 2024524371A JP 2024524371 A JP2024524371 A JP 2024524371A JP 2024540994 A5 JP2024540994 A5 JP 2024540994A5
Authority
JP
Japan
Prior art keywords
dna
cytoplasmic
inhibitor
sensing inhibitor
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074084 external-priority patent/WO2023004437A1/en
Publication of JP2024540994A publication Critical patent/JP2024540994A/ja
Publication of JP2024540994A5 publication Critical patent/JP2024540994A5/ja
Pending legal-status Critical Current

Links

JP2024524371A 2021-07-23 2022-07-22 非ウイルス性ｄｎａ送達のための方法および組成物 Pending JP2024540994A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203451P 2021-07-23 2021-07-23
US63/203,451 2021-07-23
PCT/US2022/074084 WO2023004437A1 (en) 2021-07-23 2022-07-22 Method of enhancing gene therapy by targeting cgas-sting pathway

Publications (2)

Publication Number Publication Date
JP2024540994A JP2024540994A (ja) 2024-11-06
JP2024540994A5 true JP2024540994A5 (enExample) 2025-07-25

Family

ID=84980517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524371A Pending JP2024540994A (ja) 2021-07-23 2022-07-22 非ウイルス性ｄｎａ送達のための方法および組成物

Country Status (10)

Country Link
US (1) US20240350667A1 (enExample)
EP (1) EP4373946A4 (enExample)
JP (1) JP2024540994A (enExample)
KR (1) KR20240083170A (enExample)
CN (1) CN117980487A (enExample)
AU (1) AU2022316228A1 (enExample)
CA (1) CA3230386A1 (enExample)
CO (1) CO2024002065A2 (enExample)
IL (1) IL311167A (enExample)
WO (1) WO2023004437A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054901A1 (en) * 2022-09-09 2024-03-14 Spark Therapeutics, Inc. Piperazine compounds
CN117682973B (zh) * 2022-09-26 2026-03-20 中国药科大学 磺酰胺类化合物及其医药用途
WO2024211480A2 (en) * 2023-04-05 2024-10-10 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
WO2025265081A1 (en) * 2024-06-21 2025-12-26 Stylus Medicine, Inc. cGAS-STING PATHWAY INHIBITORS AND USES THEREOF
CN118908937B (zh) * 2024-07-10 2025-07-15 中山大学中山眼科中心 一种具有sting蛋白降解作用的化合物及其制备方法和用途
CN119185549B (zh) * 2024-10-25 2025-09-02 四川大学华西医院 Sting抑制剂在制备治疗或预防心脏骤停后综合征药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391877A1 (en) * 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
JP2016506408A (ja) * 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
ES3030658T3 (en) * 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
KR20210119416A (ko) * 2019-01-24 2021-10-05 제너레이션 바이오 컴퍼니 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
US20230040275A1 (en) * 2019-11-19 2023-02-09 Spark Therapeutics, Inc. Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disorders

Similar Documents

Publication Publication Date Title
US10709797B2 (en) Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy
JP6924744B2 (ja) Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
US8853177B2 (en) Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
US10227302B2 (en) Ionizable cationic lipid for RNA delivery
CN103333890B (zh) 治疗乙型病毒性肝炎的rna干扰制剂
JP2019532080A5 (enExample)
CN104220599A (zh) 人工核酸分子
EP3898942A1 (en) Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
ES2743600T3 (es) Métodos de tratamiento de los trastornos inflamatorios vasculares
TW201408309A (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
JP2015518710A (ja) ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
US20220305118A1 (en) Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
AU2016300141B2 (en) Therapeutic oligonucleotides
US11564884B2 (en) Cationic block polymer micelles for delivery of biological agents
WO2018193902A1 (ja) マイクロｒｎａによるｂ型肝炎ウイルスに対する抗ウイルス効果
KR20110139743A (ko) 모균증 및 다른 진균 질환의 치료를 위한 백신 조성물 및 방법
EP3329004A1 (en) Therapeutic oligonucleotides
WO2013088853A1 (ja) オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター
WO2014195693A1 (en) Prevention and treatment of atrial fibrillation
US20210198629A1 (en) Compositions and methods for increasing beiging of white adipose tissue
WO2023237726A1 (en) An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
RU2024104579A (ru) Способы и композиция для невирусной доставки днк
WO2026060527A1 (en) Methods for inhibiting adenylate cyclase type 9 (ac9) and uses thereof
WO2023215716A1 (en) Compositions and methods for treatment of cancer